Fortress Biotech Inc Pref Share FBIOP
Trading Information
- Previous Close Price
- $14.65
- Day Range
- $13.46–14.65
- 52-Week Range
- $6.40–18.91
- Bid/Ask
- $13.80 / $14.00
- Market Cap
- $47.64 Mil
- Volume/Avg
- 19,115 / 12,528
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 16.00%
- Dividend Yield (Forward)
- 16.00%
- Total Yield
- 15.07%
Company Profile
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 186
- Website
- https://www.fortressbiotech.com
Comparables
Valuation
|
Metric
|
FBIOP
|
VRCA
|
CRNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 14.57 | 5.44 |
Price/Sales | — | 60.08 | 622.39 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FBIOP
|
VRCA
|
CRNX
|
|---|---|---|---|
Quick Ratio | 1.13 | 4.34 | 12.92 |
Current Ratio | 1.38 | 4.55 | 13.07 |
Interest Coverage | −12.15 | −16.60 | — |
Quick Ratio
FBIOP
VRCA
CRNX
Profitability
|
Metric
|
FBIOP
|
VRCA
|
CRNX
|
|---|---|---|---|
Return on Assets (Normalized) | −64.86% | −70.68% | −38.81% |
Return on Equity (Normalized) | −499.38% | −112.62% | −44.79% |
Return on Invested Capital (Normalized) | −123.14% | −77.30% | −45.62% |
Return on Assets
FBIOP
VRCA
CRNX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tmmybwqp | Mmxsq | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mypnrhyt | Zdbfdss | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jgkrmbky | Cjhqmy | $98.8 Bil | |
MRNA
| Moderna Inc | Dymbsvqf | Vvwh | $38.8 Bil | |
ARGX
| argenx SE ADR | Kqqkwcxw | Pfsy | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Qldmjnsr | Cwqzf | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rnsqhjthw | Pmbwxmz | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Trqrkmthb | Fskdl | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hbqgrvpb | Qqntvq | $12.4 Bil | |
INCY
| Incyte Corp | Bzglkfnd | Qyysm | $11.9 Bil |